InvestorsHub Logo

ada

Followers 54
Posts 6823
Boards Moderated 0
Alias Born 11/08/2006

ada

Re: charhorse post# 698

Thursday, 08/23/2007 9:41:25 AM

Thursday, August 23, 2007 9:41:25 AM

Post# of 1639
Thanks for you opinion and comments, balance is good on a board. My comments;
They have not shown a profit yet because they are transitioning from R&D to product sales.
I never heard anything regarding your comments about their marketing savvy.
Yes dilution sucks. I believe it is already priced in.
You may be right about the press releases, although they have not had a significantly impacting one in a while.
Hopefully most on this board sold when the pps was high. I have been open with my moves and only hold a small position right now. I am waiting to see what happens.
They are on the way to making a profit.
They did have a product returned by one retailer, but it on amounted to a $1.4 mil loss.

Some DD from the filings:

Anticipates revenues of approx $42.2 million for 2007, an increase of almost 300% compared to 2006

Sales of the Branded Products Group were $13.6 million for the three month period ended March 31, 2007 compared to $34 thousand for the same period a year ago

Anticipate a net loss for 2007 of $18.2 million. This includes a one-time net charge of $1.4 million in the fourth quarter for the return of Selenomax®.

The net loss for the year reflects the investments made by the Company to transition from a research and development-focused company selling chromium picolinate as an ingredient, to a sales and marketing-driven company selling branded consumer products

Preparing for the Fall 2007 launches of Advanced Memory FormulaTM and Diabetes Essentials®, a line of nutritional supplements for people with type-2 diabetes. Major retailers and key regional retailers have already placed purchase orders for both products.

The chromium category grew by 37.1% in the drug channel, and Chromax® became the #1 selling chromium brand at retail

Chromium picolinate was incorporated as an ingredient into Ross/Abbott’s Glucerna, the leading diabetes nutrition shake, Coca-Cola, Minute Maid Multi and, in the past month, a newly launched Diet Coke

Iceland Health direct response sales grew 15% on an annualized basis since its acquisition in August 2006

Nutrition 21 expects revenue for fiscal year 2008 to be in the range of approximately $70 to $80 million, a 66% to 94% increase over our preliminary estimates for fiscal 2007 revenue

"I tremble for my country when I reflect that God is just." - Thomas Jefferson

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.